Author: Healio ophthalmology

L-shaped scleral incision may be ideal for IOL explantation, insertion

In intraocular surgery, the placement of an incision has a lot of significance pertaining to the amount of surgically induced astigmatism and the wound architecture. Taking into consideration the anatomical location, among the various types of incisions, scleral incisions have played a significant role in phacoemulsification and in small-incision cataract surgery. A “J-shaped” incision, an “inverse J-shaped” incision and an “L-shaped” incision have been described previously by surgeons in both peer- and non-peer-reviewed literature, and they have been employed for performing phacoemulsification and also for introducing an IOL.The length and (Read more...)

NSAIDs may inhibit prostaglandin release in femtosecond cataract surgery

Pretreatment with NSAIDs reduced prostaglandin release in patients undergoing femtosecond laser-assisted cataract surgery, according to a study.“Therefore, it has potential to limit intraoperative laser-induced miosis,” the study authors said. “Previous studies detected elevated prostaglandin levels after femtosecond laser treatment and identified them as a potential mediator for laser-induced miosis.”

I-Ring ofrece una nueva estrategia para la administración intraoperativa de las pupilas pequeñas

La visualización adecuada de un lente con cataratas es esencial para una facoemulsificación y una implantación de LIO seguras. La visualización comprometida con lente debida a una cobertura parcial del iris, en casos en que la pupila es menor que 5 mm, puede presentar varios desafíos al cirujano de cataratas y puede ocasionar complicaciones intraoperativas incluido el daño a los tejidos con sangrado y miosis secundarios, rasgadura capsular posterior, caída del núcleo y pérdida vítrea con posibles complicaciones retinales secundarias. La dificultad quirúrgica con una pupila chica puede complementarse con (Read more...)

I-Ring oferece nova estratégia para a gestão intraoperatória de pupila pequena

A visualização adequada da lente cataratosa é essencial para uma facoemulsificação segura e o implante da LIO. Uma visão da lente comprometida devido à cobertura parcial da íris, nos casos de pupila menor que 5 mm, pode apresentar vários desafios para o cirurgião de catarata e resultar em possíveis complicações intraoperatórias, incluindo dano do tecido da íris com sangramento secundário e miose, rasgamento do esfíncter pupilar, rasgamento capsular posterior, núcleo caído e perda de vítreo com possíveis complicações secundárias da retina. A dificuldade cirúrgica com uma pupila pequena pode ser (Read more...)

FDA gives greenlight for phase 2 study of travoprost with iDose delivery system

The FDA will allow Glaukos to initiate a U.S. investigational new drug phase 2 study of a travoprost intraocular implant with the iDose delivery system in patients with glaucoma, according to a press release. “We are very pleased that the FDA is allowing this trial to begin several months in advance of our original target date,” Thomas Burns, president and CEO of Glaukos, said in the release.

Publication Exclusive: Pregnant woman presents with floaters and decreased vision

A 32-year-old pregnant woman at 31 weeks’ gestational age was referred to the New England Eye Center for a 1-week history of floaters and decreased vision in the left eye. She complained of 1 day of photophobia and left eye pain.Ocular history was unremarkable. Medical history included prior cesarean section, hepatitis C and spinal desmoid tumors resected and treated with doxorubicin. She had a history of intravenous drug use and stated the last episode was 8 months before presentation. She lived in a rural area with exposure to many animals (Read more...)

Valeant Pharmaceuticals names interim CEO

Valeant Pharmaceuticals International announced in a press release that it has appointed Howard B. Schiller as interim CEO.Schiller was Valeant’s chief financial officer from December 2011 through June 2015 and has served on Valeant’s Board of Directors since 2012, according to the release. J. Michael Pearson, Valeant’s CEO, is on medical leave of absence and remains in the hospital where he is being treated for pneumonia, and the timing of his expected return is uncertain, the release stated.